Skip to main content

International Journal of Phytomedicine and Phytotherapy

Table 5 Experimental models for anti-fibrotic effects of Silybum marianum

From: The potential of silymarin for the treatment of hepatic disorders

Model Silymarin doses Effect
CCl4 in transgenic mice 200 mg/kg Ex vivo reduction of the genes Cox6a2, 7a1, Cox8b [113]
CCl4 50 mg/kg Anti-inflammatory effect, HSC activation, mast cell stabilization, TGFβ secretion[109]
Thioacetamid 150 mg/kg Body weight ↓, serum cholesterol↓, TG↓, liver size ↑, ALT/AST↓,[110]
CCl4 100 mg/kg i.p. (non therapeutic route) Reduction of hepatic collagen content 18 %, Reduction hepatic fibrosis score 47 % [111]
CCl4 20 or 100 mg/kg Reduction of inflammatory and fibrotic effects [131]